Multicenter Registry of early and Late Clinical Outcomes to Everolimus-eluting Cobalt-chromium Stent In patients with ST-elevation Acute Myocardial Infarction - XIENCE STEMI Registry

onprofit Organization Nakanihon PCI society0 个研究点目标入组 400 人开始时间: 2016年2月16日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients participating in the other ongoing registry or clinical study(except post-marketing surveillance of CoCr-EES), or receiving treatment which may impact on endpoints of this study. 2)Patients presenting with cardiogenic shock 3)Patients for whom 9-month, 12-month and 36-month CAG and clinical follow up is considered difficult (patient's residence should also be taken into account) 4)Patients with responsible lesion in left main trunk 5)Patients with renal insufficiency or with chronic renal failure with serum creatinine level of 2.0mg/dL or higher at visit 6)Patients on hemodialysis 7)Patients with a known history of adverse drug reactions to aspirin, or clopidogrel or prasugrel (This may not apply if safety of ticlopidine is confirmed as an alternative drug.) 8)Patients who are below the age of 20 9)Women who were positive in pregnancy test or wish to become pregnant during study duration 10)Patients who newly developed AMI attributable to the prior stented site 11)Patients with a known history of allergy to drug, polymer, metal, and other materials used in CoCr-EES 12)Patients diagnosed with hepatic insufficiency 13)Patients with target lesion in saphenous vein graft 14)Patients with active malignant tumor

发起方

onprofit Organization Nakanihon PCI society